Skip to main content
Erschienen in:

02.10.2024 | REVIEW

Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology

verfasst von: Marius Ilié, Vivien Lake, Enrique de Alava, Serena Bonin, Sandra Chlebowski, Aurélie Delort, Elisabeth Dequeker, Raed Al-Dieri, Arjan Diepstra, Olli Carpén, Catarina Eloy, Ambrogio Fassina, Falko Fend, Pedro L. Fernandez, Gregor Gorkiewicz, Simon Heeke, Rui Henrique, Gerald Hoefler, Pablo Huertas, Michael Hummel, Karl Kashofer, Jeroen van der Laak, Rocio Martinez de Pablos, Fernando Schmitt, Ed Schuuring, Giorgio Stanta, Wim Timens, Benedikt Westphalen, Paul Hofman

Erschienen in: Virchows Archiv | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Despite advancements in precision medicine, many cancer patients globally, particularly those in resource-constrained environments, face significant challenges in accessing high-quality molecular testing and targeted therapies. The considerable heterogeneity in molecular testing highlights the urgent need to harmonize practices across Europe and beyond, establishing a more standardized and consistent approach in MP laboratories. Professionals, especially molecular pathologists, must move beyond traditional education to cope with this heterogeneity. This perspective addresses critical issues in molecular pathology (MP), such as limited access to high-quality molecular testing, leading to disparities in cancer treatment, and the consequences of inconsistent practices. Recognizing the necessity for a standardized framework for education to address these issues, educational programs play a pivotal role in updating professionals’ skills to achieve standardization in MP. European experts from the Steering Committee, the Pathology Section of the European Union of Medical Specialists, and the European Society of Pathology have proposed creating a comprehensive Master’s degree program called the “European Masters in Molecular Pathology” (EMMP). This program emerges as a strategic response to the demand for a specialized and standardized framework for education in MP, catering to professionals who concurrently work and study. The program’s design aligns with evidence-based education methods, ensuring effective learning and engagement while integrating computational pathology to analyze complex molecular data, enhance diagnostic accuracy, and improve treatment outcomes. EMMP’s structured curriculum, strategic partnerships, and regular updates underscore its significance in standardizing MP practices. Exploring future developments, this perspective delves into technology integration and interdisciplinary collaboration, anticipating ongoing advances and harmonization. Challenges and future directions in MP education are discussed, emphasizing the necessity for dynamic curriculum updates, seamless technology integration, and interdisciplinary cooperation. This perspective underscores EMMP’s pivotal role in preparing pathologists for this dynamic field, advocating continuous advancements in education and training to uphold excellence in MP practices and maintain the highest patient care standards.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28:658–665CrossRefPubMed Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28:658–665CrossRefPubMed
2.
Zurück zum Zitat Akhoundova D, Rubin MA (2022) Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell 40:920–938CrossRefPubMed Akhoundova D, Rubin MA (2022) Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell 40:920–938CrossRefPubMed
3.
Zurück zum Zitat Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J et al (2022) Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer 176:70–77CrossRefPubMed Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J et al (2022) Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer 176:70–77CrossRefPubMed
4.
Zurück zum Zitat de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R et al (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health - Europe 38:100838CrossRefPubMed de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R et al (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health - Europe 38:100838CrossRefPubMed
5.
Zurück zum Zitat Hofman P, Calabrese F, Kern I, Adam J, Alarcao A, Alborelli I et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8:101628CrossRefPubMedPubMedCentral Hofman P, Calabrese F, Kern I, Adam J, Alarcao A, Alborelli I et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8:101628CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bruno DS, Hess LM, Li X, Su EW, Patel M (2022) Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 6:e2100427CrossRefPubMed Bruno DS, Hess LM, Li X, Su EW, Patel M (2022) Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 6:e2100427CrossRefPubMed
7.
Zurück zum Zitat Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Empowering quality data - the Gordian knot of bringing real innovation into healthcare system. Diagnosis (Berl) 10:140–157CrossRefPubMed Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Empowering quality data - the Gordian knot of bringing real innovation into healthcare system. Diagnosis (Berl) 10:140–157CrossRefPubMed
8.
Zurück zum Zitat Normanno N, Apostolidis K, de Lorenzo F, Beer PA, Henderson R, Sullivan R et al (2022) Cancer biomarkers in the era of precision oncology: addressing the needs of patients and health systems. Semin Cancer Biol 84:293–301CrossRefPubMed Normanno N, Apostolidis K, de Lorenzo F, Beer PA, Henderson R, Sullivan R et al (2022) Cancer biomarkers in the era of precision oncology: addressing the needs of patients and health systems. Semin Cancer Biol 84:293–301CrossRefPubMed
9.
Zurück zum Zitat Horgan D, Van den Bulcke M, Malapelle U, Troncone G, Normanno N, Capoluongo ED et al (2024) Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems. Heliyon 10:e23914CrossRefPubMed Horgan D, Van den Bulcke M, Malapelle U, Troncone G, Normanno N, Capoluongo ED et al (2024) Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems. Heliyon 10:e23914CrossRefPubMed
10.
Zurück zum Zitat Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491–1505CrossRefPubMed Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491–1505CrossRefPubMed
11.
Zurück zum Zitat Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A et al (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339–357CrossRefPubMed Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A et al (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339–357CrossRefPubMed
12.
Zurück zum Zitat Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare (Basel) 11:431CrossRefPubMed Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare (Basel) 11:431CrossRefPubMed
13.
Zurück zum Zitat Moulin P, Grunberg K, Barale-Thomas E, der Laak JV (2021) IMI-Bigpicture: a central repository for digital pathology. Toxicol Pathol 49:711–713CrossRefPubMed Moulin P, Grunberg K, Barale-Thomas E, der Laak JV (2021) IMI-Bigpicture: a central repository for digital pathology. Toxicol Pathol 49:711–713CrossRefPubMed
14.
Zurück zum Zitat Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H (2020) The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Arch 476:491–497CrossRefPubMedPubMedCentral Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H (2020) The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Arch 476:491–497CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A et al (2023) Implementation of precision medicine in healthcare-a European perspective. J Intern Med 294:437–454CrossRefPubMed Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A et al (2023) Implementation of precision medicine in healthcare-a European perspective. J Intern Med 294:437–454CrossRefPubMed
16.
Zurück zum Zitat Laudadio J, McNeal JL, Boyd SD, Le LP, Lockwood C, McCloskey CB et al (2015) Design of a genomics curriculum: competencies for practicing pathologists. Arch Pathol Lab Med 139:894–900CrossRefPubMed Laudadio J, McNeal JL, Boyd SD, Le LP, Lockwood C, McCloskey CB et al (2015) Design of a genomics curriculum: competencies for practicing pathologists. Arch Pathol Lab Med 139:894–900CrossRefPubMed
17.
Zurück zum Zitat Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ (2022) Molecular pathology education: a suggested framework for primary care resident training in genomic medicine: a report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn 24:430–441CrossRefPubMed Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ (2022) Molecular pathology education: a suggested framework for primary care resident training in genomic medicine: a report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn 24:430–441CrossRefPubMed
18.
Zurück zum Zitat Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E et al (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931CrossRefPubMed Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E et al (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931CrossRefPubMed
20.
Zurück zum Zitat Rangachari D, Im A, Brondfield S (2022) Moving from theory to practice in oncology education when virtual is your reality. Am Soc Clin Oncol Educ Book 42:1–10PubMed Rangachari D, Im A, Brondfield S (2022) Moving from theory to practice in oncology education when virtual is your reality. Am Soc Clin Oncol Educ Book 42:1–10PubMed
21.
Zurück zum Zitat Jang HY, Kim HJ (2020) A meta-analysis of the cognitive, affective, and interpersonal outcomes of flipped classrooms in higher education. Educ Sci 10:115CrossRef Jang HY, Kim HJ (2020) A meta-analysis of the cognitive, affective, and interpersonal outcomes of flipped classrooms in higher education. Educ Sci 10:115CrossRef
22.
Zurück zum Zitat Horgan D, Curigliano G, Riess O, Hofman P, Buttner R, Conte P et al (2022) Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe. J Pers Med 12:72CrossRefPubMedPubMedCentral Horgan D, Curigliano G, Riess O, Hofman P, Buttner R, Conte P et al (2022) Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe. J Pers Med 12:72CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Horgan D, Bulcke MVD, Malapelle U, Normanno N, Capoluongo ED, Prelaj A et al (2024) Aligning cancer research priorities in Europe with recommendations for conquering cancer: a comprehensive analysis. Healthcare (Basel) 12:259CrossRefPubMed Horgan D, Bulcke MVD, Malapelle U, Normanno N, Capoluongo ED, Prelaj A et al (2024) Aligning cancer research priorities in Europe with recommendations for conquering cancer: a comprehensive analysis. Healthcare (Basel) 12:259CrossRefPubMed
Metadaten
Titel
Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology
verfasst von
Marius Ilié
Vivien Lake
Enrique de Alava
Serena Bonin
Sandra Chlebowski
Aurélie Delort
Elisabeth Dequeker
Raed Al-Dieri
Arjan Diepstra
Olli Carpén
Catarina Eloy
Ambrogio Fassina
Falko Fend
Pedro L. Fernandez
Gregor Gorkiewicz
Simon Heeke
Rui Henrique
Gerald Hoefler
Pablo Huertas
Michael Hummel
Karl Kashofer
Jeroen van der Laak
Rocio Martinez de Pablos
Fernando Schmitt
Ed Schuuring
Giorgio Stanta
Wim Timens
Benedikt Westphalen
Paul Hofman
Publikationsdatum
02.10.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 5/2024
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-024-03933-2

Neu im Fachgebiet Pathologie

Pathologie der Milz

Nach einer Beschreibung der Milzanatomie und Darstellung der diagnostisch wichtigsten immunhistochemischen Färbungen zur Identifizierung der normalen Milzkompartimente werden am Beispiel eines nordafrikanischen Patienten mit rezentem …

Molekular definierte Nierenzellkarzinome 2025

Im Zuge der Überarbeitung der WHO-Klassifikation im Jahr 2022 konnten für mehrere Nierenzellkarzinome (NZK), die sich zuvor nicht eindeutig den bis dahin definierten Tumortypen zuordnen ließen, jedoch gemeinsame morphologische und molekulare …

Wichtige Änderungen in der WHO-Klassifikation der Hodentumoren 2022

In der 5. Auflage der „WHO-Klassifikation der Tumoren der ableitenden Harnwege und des männlichen Genitaltrakts“ sind bedeutende Anpassungen an den bisherigen Klassifikationen vorgenommen worden. Diese betreffen bei den Keimzelltumoren des Hodens …

DNA mixture deconvolution using fully continuous models EuroForMix and EFMrep

  • Open Access
  • Originalien

Mixture deconvolution is a powerful tool for inferring individual DNA profiles from DNA mixtures for subsequent transmission to a database or database queries. To carry out deconvolution, a mixed trace can be interpreted either manually by an …